


IDS 3/11/03

Sheet 1 of 1

RECEIVED

Form PTO-1449 (Rev. 8-88)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. C-3409/1/US		Serial No. 10/008,222	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant			
				He, X.			
				Filing Date December 5, 2001		Group No. 1619	
U.S. PATENT DOCUMENTS							
Examiner Initial*	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate	
J	5,037,657	Aug 06, 1991	Jones et al.	424	466		
	5,211,957	May 18, 1993	Hagemann et al.	424	466		
	5,223,264	Jun 29, 1993	Wheling et al.	424	466		
	5,424,075	Jun 13, 1995	Daher et al.	424	465		
	5,762,951	Jun 09, 1998	Maasz et al.	424	439		
	5,807,577	Sep 15, 1998	Ouali	424	466		
FOREIGN PATENT DOCUMENTS							
Examiner Initial*	Document Number	Date	Country	Class	Subclass	Translation Yes No	
J	EP 0 396 335	Feb 02, 1994	EP	A61K	9/20		
	EP 0 476 696	Jun 21, 1995	EP	A61K	9/16		
	FR 2 793 685	Nov 24, 2000	FR	A61K	31/05		X
J	1 595 220	Aug 12, 1981	GB	A61K	9/46		
	WO 95/03785	Feb 09, 1995	WO	A61K	9/00		
OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)							
J	Lieberman et al., ed. <i>Pharmaceutical Dosage Forms: Tablets</i> , Volume 1, 2 nd ed., Marcel Dekker, 34-36, 285-328. (1989).						
J	United States Pharmacopeia, 24 th ed., 2254-2304. (2000).						
Examiner	Date Considered			8/04			
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							


 MAR 12 2003
 TECH CENTER 1600/2900